Company intelligence / Profile preview

X4 Pharmaceuticals, Inc.

Boston, Massachusetts, United States of Americainvestors.x4pharma.com ↗

Ownership: Public · XFOR
Employees: ~143
Development stage: Commercial

Overview

X4 Pharmaceuticals received FDA approval for XOLREMDI™ (Mavorixafor) on April 26, 2024, for treating patients aged 12 and older with WHIM syndrome to increase mature neutrophils and lymphocytes in circulation. The company reported Q1 2025 financial results on May 1, 2025, and announced a strategic restructuring on February 6, 2025.

Therapeutic areas: HematologyImmunologyInfectious Diseases
Modalities: Small molecule drugsMonoclonal antibodies
Industry: Biotech

Drug pipeline

10 assets

mavorixafor

Approved

9 more assets in the full pipeline.

Request access →

Partnerships

Hercules Capital (financing partner)

Financials

Market cap: $320.7M
Total revenue: $8.8M
Enterprise value: $189.9M

Beyond the preview

Go deeper on X4 Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on X4 Pharmaceuticals, Inc..

Explore the full profile